An immunohistochemical study of leu 7 and PCNA expression in thyroid neoplasms.
Monoclonal Antibody (MoAb) HNK, or anti-leu-7, is reactive with several neuroendocrine and nonneuroendocrine tumors. The aim of this study is to examine anti-leu-7 reactivity in thyroid neoplasms and its relationship to cellular proliferation as determined by anti-PCNA reactivity. The expression of anti-leu-7 in 56 thyroid neoplasms (24 papillary carcinomas, 14 follicular carcinomas, two medullary carcinomas and 16 follicular adenomas) was examined immunohistochemically. Papillary and follicular thyroid carcinomas reacted with anti-leu-7 in a membranous and cytoplasmic pattern in 88% and 93% of cases, respectively. The adjacent benign tissues were nonreactive. Only eight cases diagnosed as follicular adenomas were reactive with anti-leu-7. Furthermore, the mean proliferative index (PI), as measured by the percentage of nuclei immunoreactive with anti-PCNA, was greater than 30% in all thyroid neoplasms reactive with anti-leu-7. The PI was 58% for papillary carcinomas and 68% and 48% for follicular carcinomas, and follicular adenomas, respectively. Lesions originally classified as follicular adenomas that were nonreactive with anti-leu-7 had a PI of 24% and were reclassified as hyperplastic nodules. These data suggest that anti-leu-7 may be useful for characterizing thyroid neoplasia.
Fucich
L F
LF
Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Freeman
S M
SM
Marrogi
A J
AJ
D000236:Adenoma / Q000276:immunology* / Q000473:pathology; D018959:CD57 Antigens / Q000032:analysis*; D018276:Carcinoma, Medullary / Q000276:immunology* / Q000473:pathology; D002291:Carcinoma, Papillary / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*; D013964:Thyroid Neoplasms / Q000276:immunology* / Q000473:pathology
D018959:CD57 Antigens; D018809:Proliferating Cell Nuclear Antigen